{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:13:53Z","timestamp":1740147233728,"version":"3.37.3"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,5]],"date-time":"2017-11-05T00:00:00Z","timestamp":1509840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>The single\u2010pill combination (SPC) comprising nebivolol (5\u00a0mg), a vasodilatory \u03b2<jats:sub>1<\/jats:sub>\u2010selective antagonist\/\u03b2<jats:sub>3<\/jats:sub>\u2010agonist, and valsartan (80\u00a0mg), a renin\u2010angiotensin\u2010aldosterone system inhibitor, is the only Food and Drug Administration\u2013approved \u03b2\u2010blocker\/renin\u2010angiotensin\u2010aldosterone system inhibitor SPC for hypertension. Additive effects of four nebivolol\/valsartan SPC doses (5\u00a0mg\/80\u00a0mg, 5\/160\u00a0mg, 10\/160\u00a0mg, 10\/320\u00a0mg nebivolol\/valsartan) were compared with five Food and Drug Administration\u2013approved non\u2013\u03b2\u2010blocker\/renin\u2010angiotensin\u2010aldosterone system inhibitor SPCs (aliskiren\/hydrochlorothiazide, aliskiren\/amlodipine, valsartan\/amlodipine, aliskiren\/valsartan, and telmisartan\/amlodipine). Additivity is the ratio of placebo\u2010adjusted SPC blood pressure (BP) reduction to the placebo\u2010adjusted monotherapy component BP reduction sums. A weighted average of comparator scores was calculated and compared vs nebivolol\/valsartan. Additivity ratio scores for nebivolol\/valsartan SPCs (diastolic BP range: 0.735\u20130.866; systolic BP range: 0.717\u20130.822) were similar to the comparator weighted average (diastolic BP: 0.837; systolic BP: 0.825). Among the nebivolol\/valsartan SPCs, 5\/80\u00a0mg had the greatest additivity (diastolic BP: 0.866; systolic BP: 0.822). BP reduction contributions with monotherapy were similar for nebivolol\/valsartan 5\/80 mg SPC. Additivity scores for nebivolol\/valsartan and select non\u2013\u03b2\u2010blocker\/renin\u2010angiotensin\u2010aldosterone system inhibitor SPCs were comparable.<\/jats:p>","DOI":"10.1111\/jch.13132","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T15:02:12Z","timestamp":1516633332000},"page":"143-149","source":"Crossref","is-referenced-by-count":6,"title":["Additivity of nebivolol\/valsartan single\u2010pill combinations versus other single\u2010pill combinations for hypertension"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-2399","authenticated-orcid":false,"given":"Jack","family":"Ishak","sequence":"first","affiliation":[{"name":"Evidera  St\u2010Laurent QC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rael","sequence":"additional","affiliation":[{"name":"Evidera  San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Punzi","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center  Dallas TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Gradman","sequence":"additional","affiliation":[{"name":"Temple University School of Medicine  Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Prescott Medical Communications Group  Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[{"name":"Allergan plc Harborside Financial Center  Jersey City NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjida","family":"Ali","sequence":"additional","affiliation":[{"name":"Allergan plc Harborside Financial Center  Jersey City NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Allergan plc Harborside Financial Center  Jersey City NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Neutel","sequence":"additional","affiliation":[{"name":"Orange County Research Center  Tustin CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.096156"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318282ab8f"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.09.038"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2010.02.005"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0020-9"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641968809046803"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1751-7176.2010.00341.x","article-title":"Effect of combining extended\u2010release carvedilol and lisinopril in hypertension: results of the COSMOS study","volume":"12","author":"Bakris GL","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/AC.65.5.2056244"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2009.11.020"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1020790"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-007-0050-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.066"},{"volume-title":"US Prescribing Information","year":"2016","author":"Bystolic\u00ae (Nebivolol Tablets)","key":"e_1_2_9_15_1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00151642-200512010-00005"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200808010-00005"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001490"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02028.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.543416"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00666.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60614-0"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3280103a6b"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02967.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2012.42"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61124-6"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.03.018"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2009.00098.x"},{"key":"e_1_2_9_29_1","unstructured":"US Food and Drug Administration.Drugs@FDA: FDA approved drug products.2016.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/. Accessed March 1 2016."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00387.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.33"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.jash.2015.03.055","article-title":"Efficacy and tolerability of nebivolol added to RAAS inhibitors","volume":"9","author":"Neutel J","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000093060"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0435-5"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319460-000000000-00000"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.07.020"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753944712459593"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.13132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.13132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:49:54Z","timestamp":1695574194000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.13132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/jch.13132"],"URL":"https:\/\/doi.org\/10.1111\/jch.13132","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"type":"print","value":"1524-6175"},{"type":"electronic","value":"1751-7176"}],"subject":[],"published":{"date-parts":[[2017,11,5]]}}}